Skip to content

Pfizer Inc Price, Chart & Factor Exposure

Free Data & Analytics Access

Next earnings: Tue, Feb 2, 2027, before the market opens · estimates and history

Pfizer Inc · E.PFE.NYSE · United States
Use symbol E.PFE.NYSE in our API & Excel add-in to retrieve this data ↓
29.95
(+0.02%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 50%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 21.19%

Pfizer Inc Forecast

Pfizer Inc short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 21.2% a year, a typical one-standard-deviation range is 29.06–30.84 over a week, 28.12–31.78 over a month and 23.60–36.30 over a year. (Signals as of 1 Nov 2026.)

Pfizer Inc Price Chart

MacroFinance.ai
Market/MacroIndicatorNowChangeRange
Quantitative
Pfizer Inc
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Pfizer Inc
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Pfizer Inc
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Pfizer Inc
P/E
42.71x
Stretched vs own history
QoQ +15.7%
YoY +193.4%
now 42.708314.59 low42.71 high
ⓘP/E As of 22 Nov 2026.See Pfizer Inc returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
Pfizer Inc
P/S
2.71x
Mid-range vs own history
QoQ +7.8%
YoY +18.8%
now 2.70722.19 low2.73 high
ⓘP/S As of 22 Nov 2026.See Pfizer Inc returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Pfizer Inc
P/B
1.94x
Mid-range vs own history
QoQ +3.1%
YoY +25.5%
now 1.93531.54 low2.04 high
ⓘP/B As of 22 Nov 2026.See Pfizer Inc returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Pfizer Inc
EV/EBITDA
16.38x
Stretched vs own history
QoQ +4.5%
YoY +60.1%
now 16.383910.25 low16.71 high
ⓘEV/EBITDA As of 22 Nov 2026.See Pfizer Inc returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Pfizer Inc
EV/Sales
3.47x
Mid-range vs own history
QoQ +4.5%
YoY +14.7%
now 3.46793 low3.54 high
ⓘEV/Sales As of 22 Nov 2026.See Pfizer Inc returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Pfizer Inc
FCF Yield
6.8%
Mid-range vs own history
QoQ −0.4%
YoY −5.6%
now 6.84335.64 low7.48 high
ⓘFCF Yield As of 22 Nov 2026.See Pfizer Inc returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Pfizer Inc
Earnings Yield
2.3%
Weak vs own history
QoQ −13.5%
YoY −65.9%
now 2.34152.34 low6.86 high
ⓘEarnings Yield As of 22 Nov 2026.See Pfizer Inc returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Pfizer Inc
Dividend Yield
5.7%
Mid-range vs own history
QoQ −7.1%
YoY −16.2%
now 5.6855.63 low7.06 high
ⓘDividend Yield As of 22 Nov 2026.See Pfizer Inc returns when Dividend Yield looked like now →Opens Return analysis with the filter Dividend Yield within ±5% of today
Pfizer Inc
Market Cap
$172.2B
Mid-range vs own history
QoQ +7.7%
YoY +20.4%
now 172242.45138,518 low173,933 high
ⓘMarket Cap As of 22 Nov 2026.See Pfizer Inc returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Pfizer Inc
Net Debt
$48.4B
Mid-range vs own history
QoQ −6.0%
YoY +3.6%
now 4839946,728 low53,820 high
ⓘNet Debt As of 22 Nov 2026.See Pfizer Inc returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Pfizer Inc
Net Debt / EBITDA
3.59x
Mid-range vs own history
QoQ −5.8%
YoY +42.7%
now 3.59392.52 low3.82 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Pfizer Inc returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Pfizer Inc
Current Ratio
1.42x
Mid-range vs own history
QoQ +12.0%
YoY +10.6%
now 1.41861.16 low1.42 high
ⓘCurrent Ratio As of 22 Nov 2026.See Pfizer Inc returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Pfizer Inc
Quick Ratio
1.10x
Mid-range vs own history
QoQ +14.6%
YoY +13.8%
now 1.10280.87 low1.1 high
ⓘQuick Ratio As of 22 Nov 2026.See Pfizer Inc returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Pfizer Inc
Interest Coverage
2.57x
Mid-range vs own history
QoQ +0.5%
YoY −41.4%
now 2.57312.56 low4.39 high
ⓘInterest Coverage As of 22 Nov 2026.See Pfizer Inc returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Pfizer Inc
Debt / Equity
0.70x
Mid-range vs own history
QoQ −5.1%
YoY +5.9%
now 0.70420.66 low0.78 high
ⓘDebt / Equity As of 22 Nov 2026.See Pfizer Inc returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Pfizer Inc
Piotroski F-Score
5
Mid-range vs own history
QoQ −28.6%
YoY −37.5%
now 55 low8 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Pfizer Inc returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Pfizer Inc
Altman Z-Score
2.19
Mid-range vs own history
QoQ +4.6%
YoY +4.0%
now 2.18752.01 low2.19 high
ⓘAltman Z-Score As of 22 Nov 2026.See Pfizer Inc returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  19 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  21 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Pfizer Inc, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Pfizer Inc fundamentals: income statement, balance sheet & cash flow

Pfizer Inc reported revenue of $62.58bn and net income of $7.77bn in FY2025, the year ended 31 December 2025 — revenue down 1.6% and net income down 3.2% on the prior year. Free cash flow was $9.08bn. These figures are as reported in the filings, not restated: 41 fiscal years and 165 quarters of history, back to December 1985. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$62.58bn
-1.6%
Net income
$7.77bn
-3.2%
Gross margin
74.33%
Free cash flow
$9.08bn
-7.7%
Net debt
$66.27bn
Shares short (30 Oct 2026)
134.42m
4.58 days to cover
Pfizer Inc income statement, annual, as reported · USD billions unless stated
USD billionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue62.5863.6359.55101.1881.29
Cost of revenue16.0717.8524.9534.3430.82
Gross profit46.5145.7834.6066.8350.47
Research & development10.4410.8210.6811.4313.83
Operating income17.4114.944.4238.1220.24
EBITDA16.7818.139.5641.0330.79
Interest expense2.673.092.211.241.29
Pre-tax income7.528.021.0634.7324.31
Income tax-0.27-0.03-1.123.331.85
Net income7.778.032.1231.3721.98

Download Pfizer Inc fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.PFE.NYSE&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 41 fiscal years and 165 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Pfizer Inc

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Pfizer Inc Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Pfizer Inc; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

About Pfizer Inc (United States)

Pfizer Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Pantera Minerals Ltd

Frequently asked questions

What is Pfizer Inc?
Pfizer Inc is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the trading strategies that hold it and free historical data.
What is the latest Pfizer Inc price?
The latest close is 29.95 (1 Nov 2026), +0.02% on the day. The price at the top of the page refreshes during the trading day.
Is Pfizer Inc in an uptrend?
As of 1 Nov 2026, short-term momentum is positive (3 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Pfizer Inc?
20-day realised volatility is 21.2% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 6.1% over a month and 3.0% over a week.
What factors affect Pfizer Inc?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Pfizer Inc, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Pfizer Inc?
58 backtested tactical asset allocation strategies trade Pfizer Inc through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
Where can I download free Pfizer Inc historical data?
In the Free historical data section of this page: the last 10 years of Pfizer Inc daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Pfizer Inc historical data (last 10 years)

Browse or instantly download the last 10 years of Pfizer Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.PFE.NYSE&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-2027.4
2026-11-1927.54
2026-11-1828.06
2026-11-1728.47
2026-11-1628.86
2026-11-1328.89
2026-11-1228.83
2026-11-1129.45
2026-11-1029.36
2026-11-0929.23
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.